Ohm, if you're out there tonight, mfgola linked to
Post# of 158145
Any opinion on how their IB1363 compares with LL?
"Innovent is running phase 2 trials to test IBI363 in patients with types of lung and colorectal cancers. A global phase 3 trial in non-small cell lung cancer is expected to start in the coming months. The studies build on data in more than 1,200 patients that have persuaded Innovent IBI363 could become the backbone immuno-oncology treatment."
https://www.fiercebiotech.com/biotech/takeda-...candidates